Aclaris Therapeutics Stock Forecast, Price & News

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Aclaris Therapeutics?

Wall Street analysts have given Aclaris Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aclaris Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Aclaris Therapeutics.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. The biotechnology company earned $1.82 million during the quarter, compared to the consensus estimate of $1.78 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 67.06% and a negative net margin of 1,067.07%.
View Aclaris Therapeutics' earnings history.

How has Aclaris Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACRS stock has increased by 1,604.7% and is now trading at $18.07.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ACRS?

4 Wall Street analysts have issued 1-year target prices for Aclaris Therapeutics' stock. Their forecasts range from $26.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $36.00 in the next year. This suggests a possible upside of 99.2% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

• Neal S. Walker, President, Chief Executive Officer & Director (LinkedIn Profile)
• Frank Ruffo, Chief Financial Officer & Treasurer (LinkedIn Profile)
• David Gordon, Chief Medical Officer (LinkedIn Profile)
• Joseph B. Monahan, Chief Scientific Officer
• Kamil Ali-Jackson, Secretary, Chief Legal & Chief Compliance Officer (LinkedIn Profile)

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

Some companies that are related to Aclaris Therapeutics include Arvinas (ARVN), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Hypera (HYPMY), 23andMe (ME), Turning Point Therapeutics (TPTX), Arena Pharmaceuticals (ARNA), Karuna Therapeutics (KRTX), Galapagos (GLPG), Nektar Therapeutics (NKTR), Prothena (PRTA), Cryoport (CYRX), Insmed (INSM), ALX Oncology (ALXO) and Intra-Cellular Therapies (ITCI).
View all of ACRS's competitors.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include VR Adviser LLC (7.46%), BlackRock Inc. (5.29%), Vanguard Group Inc. (4.19%), Renaissance Technologies LLC (3.97%), FMR LLC (2.76%) and Commodore Capital LP (2.73%). Company insiders that own Aclaris Therapeutics stock include David N Gordon, Frank Ruffo, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends for Aclaris Therapeutics.

Which major investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Renaissance Technologies LLC, Ghost Tree Capital LLC, Endurant Capital Management LP, Frazier Management LLC, Samsara BioCapital LLC, Millennium Management LLC, and Acuta Capital Partners LLC. Company insiders that have sold Aclaris Therapeutics company stock in the last year include David N Gordon, Frank Ruffo, Kamil Ali-Jackson, and Neal Walker.
View insider buying and selling activity for Aclaris Therapeutics or view top insider-selling stocks.

Which major investors are buying Aclaris Therapeutics stock?

ACRS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BVF Inc. IL, State Street Corp, VR Adviser LLC, Logos Global Management LP, Commodore Capital LP, Laurion Capital Management LP, and Vanguard Group Inc..
View insider buying and selling activity for Aclaris Therapeutics or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $18.07.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $1.11 billion and generates $6.48 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 59 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at (484) 324-7933 or via email at [email protected].